Dispersed tablet of proton pump inhibitor

A technology of proton pump inhibitors and dispersible tablets, which is applied in the direction of pill delivery, organic active ingredients, inorganic non-active ingredients, etc., can solve problems such as unfavorable and timely treatment and rapid relief of pain, delayed acid suppression effect of proton pump inhibitors, etc., to achieve Considerable economic and social benefits, reduced coating process, and low production cost

Inactive Publication Date: 2007-11-07
JIANGSU AOSAIKANG PHARMA CO LTD
View PDF0 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Since proton pump inhibitors are easily degraded in an acidic environment, the usual oral preparations of proton pump inhibitors adopt enteric coating to prevent the active ingredient from degrading in gastric acid. The acid-suppressing effect of proton pump inhibitors is delayed, which is not conducive to timely treatment and rapid relief of patient suffering

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Omeprazole 20g

[0021] Sodium Bicarbonate 400g

[0022] Povidone 70g

[0023] Magnesium Stearate 10g

[0024] The above-mentioned amount of omeprazole is mixed with sodium bicarbonate and povidone through an 80-mesh sieve according to an equal amount incremental method, and the rolling method is used to make a large piece, which is granulated through a 18-mesh sieve, and magnesium stearate is added, and the mixture is uniformly mixed. After the content of the intermediate is measured, the tablet is pressed to obtain an omeprazole dispersible tablet.

Embodiment 2

[0026] Omeprazole 20g

[0027] Sodium Bicarbonate 500g

[0028] Pregelatinized starch 236g

[0029] Crospovidone 40g

[0030] Magnesium Stearate 4g

[0031] The omeprazole of the above-mentioned amount is mixed with sodium bicarbonate and pregelatinized starch by an equal amount progressive addition method and crossed through a 60-mesh sieve, rolled to make a large piece, granulated through a 16-mesh sieve, and added with crospovidone and hard sieve. Magnesium fatty acid, mix evenly, measure the content of the intermediate, and press into tablets to obtain omeprazole dispersible tablets.

Embodiment 3

[0033] Omeprazole 80g

[0034] Sodium Bicarbonate 800g

[0035] Mannitol 408g

[0036] Sodium Carboxymethyl Starch 70g

[0037] Sucralose 21g

[0038] Strawberry Flavor 7g

[0039] Micro Powder Silica 14g

[0040] The omeprazole of the above-mentioned amount is mixed with sodium bicarbonate, mannitol, sucralose, strawberry essence in an equal amount by passing through a 60 mesh sieve. Sodium starch base and micropowder silica gel are mixed uniformly, and the content of the intermediate is measured, and then pressed into tablets to obtain omeprazole dispersible tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
hardnessaaaaaaaaaa
Login to view more

Abstract

The dispersed tablet of proton pump inhibitor is used for treating gastric ulcer, duodenal ulcer, stomal ulcer and other indications. It contains at least one kind of proton pump inhibitor and at least one kind of biologically acceptable buffering agent in the weight ratio of 1 to 10-200. The proton pump inhibitor is one selected from omeprazole, S-omeprazole, pantoprazole, lansoprazole, rabeprazole, leminoprazole, tenatoprazole and their salts. The biologically acceptable buffering agent is sodium bicarbonate, sodium carbonate, magnesium carbonate, etc or their mixture.

Description

technical field [0001] A proton pump inhibitor dispersible tablet of the present invention relates to a dispersible tablet containing at least one proton pump inhibitor and at least one biologically acceptable buffer, which is used for the treatment of gastric ulcer, duodenal ulcer and anastomotic ulcer , Reflux on esophagitis, Zhuo-Ellison syndrome and other indications. Background technique [0002] Digestive system disease is one of the common frequently-occurring diseases, among which ulcer disease is the most common, its total incidence is about 10-12% of the total population, and the main age of onset is 30-50 years old. There are 400,000 people suffering from peptic ulcer in the United States every year, mainly due to smoking, drinking, emotional stress, and drug stimulation (such as ASP, indomethacin, piroxicam, etc.) %. The incidence of gastrointestinal tract in Japan was 5 to 10%, and in Germany it was 12.3%. According to the survey results of a few places in my...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/4184A61K31/4439A61K31/444A61K47/02A61K47/34A61K47/36A61K47/38A61P1/04A61K47/32
Inventor 叶东陈祥峰戴艳
Owner JIANGSU AOSAIKANG PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap